CLINICIAN EVIDENCE
Evidence Summary for Clinicians - One Page
The key OPEP evidence at a glance.
Key Findings
- A real-world matched cohort of 810 COPD patients showed lower 30-day exacerbation and hospitalisation rates with an OPEP device versus standard care (Burudpakdee, 2017).
- A systematic review and meta-analysis reported improved sputum clearance and symptom or quality-of-life outcomes with OPEP in COPD (2020).
- Three to four weeks of OPEP improved MRI-measured ventilation, dyspnoea and 6-minute-walk distance in COPD with chronic sputum (Svenningsen, 2015).
- Adding an OPEP device to standard care reduced respiratory-related readmissions and costs in post-operative patients (real-world evidence, 2018).
- Combining PEP or OPEP therapy with bronchodilator aerosol therapy improved pulmonary function versus medication alone across several studies, including randomised trials.
Validation And Regulation
An independent Griffith University review (Prof. Norman Morris) validated the AirPhysio mechanism within established airway-clearance science.
AirPhysio is TGA-listed (Australia) and US FDA 510(k)-cleared (K203209); the manufacturer holds ISO 9001 and ISO 13485 quality certification (verify current validity).
Honest Framing
Evidence is strongest for sputum clearance, symptoms, quality of life, exacerbations and ventilation; spirometry gains are not guaranteed in every cohort.
Next step Request samples, an evidence pack, or a CPD session. Health Brands SA - tshepo@therapyonthego.co.za - airphysio.co.za.
Get AirPhysio® — R945 incl. 15% VAT
Drug-free airway clearance. Fulfilled by the official SA store.
This platform records measurements taken by your health practitioner and readings you self-report. It does not diagnose or treat any condition. AirPhysio® is a trademark of its manufacturer; claims are limited to airway clearance and lung-expansion support. Items requiring specialist confirmation are marked for review before external use.